

Date of Report: 24/07/2023

## FOI - 8158 Non Small Cell Lung Cancer

Questions	Notes/Comments	Response
<b>Q1 - How many patients has your Trust treated in the past 3 months for:</b>	To provide the answer to each element of the question, data was extracted from the MKUH data-warehouse and compared with data in the SACT report and then counter validated via the Lung MDT team.	
<b>(a) Non-small cell lung cancer (NSCLC) - any treatment</b>	The response for this question is a result of all NSCLC receiving any treatment during April, May and June 2023.	2
<b>(b) Non-small cell lung cancer (NSCLC) - surgical treatment</b>	The response for this question is a result of all NSCLC receiving surgical treatment during April, May and June 2023.	0
<b>(c) Non-small cell lung cancer (NSCLC) - radiotherapy</b>	The response to this question is a result of NSCLC receiving radiotherapy during April, May and June 2023.	0
<b>(d) Non-small cell lung cancer (NSCLC) - systemic anti-cancer treatment (SACT)</b>	The response to this question is a result of NSCLC receiving systemic anti-cancer treatment during April, May and June 2023.	2
<b>Q3 - Of the NSCLC patients treated with Nivolumab in the past 3 months, how many patients received (surgery) or are scheduled to receive surgical treatment after commencement of the treatment with Nivolumab?</b>	Of the two patients identified in Question 1(d) as receiving SACT treatment, only one patient has received Nivolumab and is scheduled to receive surgical treatment after anti-cancer SACT during April, May and June 2023	1